← 返回

乳腺癌间质中 Galectin-1 的表达:三阴性乳腺癌中的预后价值

英文原题:Galectin-1 Expression in Breast Cancer Stroma: Prognostic Value in Triple-Negative Breast Cancer.

查看英文原题

Galectin-1 Expression in Breast Cancer Stroma: Prognostic Value in Triple-Negative Breast Cancer.

PubMed 2025/05/28(内容时间) Pathobiology Q3 · IF 1.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

半乳糖凝集素-1 在肿瘤巢周围形成屏障的免疫抑制效应可能构成一种免疫逃逸机制,并可解释我们在 TNBC 中发现的较差的 OS 和 PFS。由于本研究的探索性质,这些结果需要进一步确认,以探究抗半乳糖凝集素-1 疗法的潜力。

研究思路结论见上方概要

Galectin-1是一种在不同实体瘤中具有免疫抑制作用的凝集素。我们研究了三阴性乳腺癌(TNBC)中galectin-1的表达,以确定其预后价值。

我们采用组织芯片对95例TNBC手术样本进行galectin-1免疫组化检测(染色强度和百分比),并借助Kaplan-Meier估计法探讨其对总生存期和无进展生存期(PFS)的影响。同时进行了单变量和多变量Cox回归分析。

根据Kaplan-Meier曲线,与缺乏galectin-1间质界面染色的TNBC患者相比,表现出强烈或≥50% galectin-1间质界面染色的TNBC患者的总生存期(OS)显著更差。Cox回归分析提示,galectin-1表达是TNBC的独立预后因素。根据间质TIL(肿瘤浸润淋巴细胞)(sTILs)的数量,仅在低sTILs(<30%)亚组中观察到基于galectin-1状态的显著生存差异。多变量分析提示,galectin-1表达是PFS的独立预后因素。

展开英文摘要原文

We examined 95 TNBC surgical samples in tissue microarrays with galectin-1 immunohistochemistry (intensity and percentage of staining) and looked for influences on overall and progression-free survivals (PFSs) with the help of Kaplan-Meier estimates. Univariable and multivariable Cox regressions were also analyzed.

According to Kaplan-Meier curves, a significantly worse overall survival (OS) was found for TNBC patients showing intense or ≥50% galectin-1 stromal interface staining versus those lacking it. Cox regression analyses suggested that galectin-1 expression was an independent prognosticator in TNBC. According to the quantity of stromal tumor-infiltrating lymphocytes (sTILs), significant survival differences depending on galectin-1 status were only seen in the low sTILs (<30%) subset. Multivariable analysis suggested that galectin-1 expression was an independent prognosticator for PFS. DISCUSSION: The immunosuppressive effects of galectin-1 forming a shield around tumor nests may form an immune escape mechanism and can explain the worse OS and PFS we found in TNBC. Owing to the exploratory nature of the study, the results need confirmation in order to investigate the potentials of anti-galectin-1 therapies.

论文信息

作者
Almási S、Krenács T、Krenács L、Cserni G
单位
Department of Pathology, Albert Szent-Gy&#xf6;rgyi Medical Centre, University of Szeged, Szeged, Hungary, szinti951023@gmail.com.Hungary
期刊
Pathobiology : journal of immunopathology, molecular and cellular biology2025
原文标识
PubMed 40435987 · DOI 10.1159/000546206